We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Eden Biodesign to offer Millipore’s Expression Technology as part of its Cell Line Development Services
News

Eden Biodesign to offer Millipore’s Expression Technology as part of its Cell Line Development Services

Eden Biodesign to offer Millipore’s Expression Technology as part of its Cell Line Development Services
News

Eden Biodesign to offer Millipore’s Expression Technology as part of its Cell Line Development Services

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Eden Biodesign to offer Millipore’s Expression Technology as part of its Cell Line Development Services"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Eden Biodesign Ltd. and Millipore Corporation announced a partnership that will provide biopharmaceutical companies with access to a powerful combination of Eden’s cGMP manufacturing and Millipore’s Ubiquitous Chromatin Opening Elements (UCOE®) expression technology.

“We are pleased to collaborate with Eden Biodesign in the complex mammalian cell development arena and have high expectations for the ongoing success of this partnership.”

As part of this agreement, Eden Biodesign will employ Millipore’s proprietary UCOE® expression technology to undertake mammalian cell line development projects and cGMP production for third-party clients.

Millipore’s UCOE® technology provides major improvements in gene expression for stably transfected mammalian cells through effects on the structure of chromatin. Cells developed using Millipore’s UCOE® technology are stable high-expressors, which means it is easier and faster for biopharmaceutical manufacturers to identify high-yielding clones with the productivity and stability required for biomanufacturing than with many other expression systems.

“We are delighted to work with a recognized industry leader like Millipore to make this extremely valuable technology available to our clients around the world,” said Roger Lias, Ph.D., president of Eden Biodesign’s North American subsidiary. “Speed-to-clinic and the ability to rapidly develop highly productive cell lines that will support economically viable production through clinical development, process scale-up and steady-state large scale commercial supply are vitally important considerations for our clients.”
Advertisement